FDA faults Biocon plant during preapproval review

Biocon Biopharmaceutical
Biocon's drug substance plant in Bengaluru, India, has run up against some FDA concerns. (Biocon)

The company today reported that the agency issued a Form 483 with five observations following a preapproval and good manufacturing practices inspection last week. It didn’t say what product it is hoping to get approved for production at the plant or what the issues are but pledged to get on them.  

“We will respond to the FDA with a Corrective and Preventive Action Plan (CAPA) and are confident of addressing these observations expeditiously. We remain committed to global standards of Quality and Compliance,” Biocon said in a statement.

RELATED: Mylan's Lantus copy derailed in U.S. again by manufacturing ills

Biocon has had some other issues with manufacturing. Just days earlier, in its quarterly report, Biocon pointed out that in August the FDA had issued an Establishment Inspection Report from the FDA stating the agency had closed its inspection of the Biologics Drug Product facility in Bengaluru. In December, the agency greenlighted the facility to manufacture the drug substance for Fulphila (pegfilgrastim), which it is making for Mylan. The drug, a blood cell booster for cancer patients, is Mylan’s knockoff of Amgen’s Neulasta.

EDITOR'S NOTE: The story was updated to indicate that the action was taken against Biocon's drug substance plant and not its biosimilar's plant. 

Read more on

Suggested Articles

Gilead Sciences will add 140 jobs to its Irish operations as part of an expansion to its Dublin distribution center, the Irish Times reported.

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

Moderna will delegate fill-finish duties for "hundreds of millions" of doses of its COVID-19 vaccine to Spain's Laboratorios Farmacéuticos Rovi.